ScienceLatest
FDA Delay Forces Biotech Closure Amid Neurocrine Deal
A recent FDA delay has led to the closure of a biotech company, impacting its operations. Additionally, there are developments regarding a deal with Neurocrine that are noteworthy for the industry.
0 upvotes
What happened
A recent FDA delay has led to the closure of a biotech company, impacting its operations.
Why it matters
Additionally, there are developments regarding a deal with Neurocrine that are noteworthy for the industry.